Lumos Diagnostics Holdings Ltd has released a press release.
Economic Evaluation of FebriDx
Filed with ASX ·
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call6ix hasn’t read this filing yet.
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- U.S FDA Deprioritises EUA Application for CoviDx
- FY21 Full Year Results
- FY21 Full Year Results Investor Presentation
- FY21 Full Year Results Media Release
- FY21 Appendix 4E
Later from Lumos Diagnostics
- Update on Economic Evaluation of FebriDx
- Monthly Activities/Appendix 4C Cash Flow Report
- LDX received authorization to sell CoviDx in Canada
- Lumos Receives Initial Orders for CoviDx In Canada
- Lumos Provides ViraDx and FebriDx Regulatory Update
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics